Next-generation sequencing and epigenome technologies: potential medical applications

References

• The human genome at ten. Nature464(7289), 649–650 (2010).
   PubMed Web of Science ®Google Scholar
• Collins F. Has the revolution arrived? Nature464(7289), 674–675 (2010).
   PubMed Web of Science ®Google Scholar
• Venter JC. Multiple personal genomes await. Nature464(7289), 676–677 (2010).
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26, 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Check Hayden E. Human genome at ten: life is complicated. Nature464(7289), 664–667 (2010).
   PubMed Web of Science ®Google Scholar
• ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, ingeras TR, Margulies EH. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature447(7146), 799–816 (2007).
   PubMed Web of Science ®Google Scholar
• Human genome at ten: the sequence explosion. Nature464(7289), 670–671 (2010).
   PubMed Web of Science ®Google Scholar
• Check Hayden E. 10,000 genomes to come. Nature462(7269), 21 (2009).
   PubMedGoogle Scholar
• International Cancer Genome Consortium: international network of cancer genome projects. Nature464, 993–998 (2010).
   PubMed Web of Science ®Google Scholar
• Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature464(7291), 999–1005 (2010).
   PubMed Web of Science ®Google Scholar
• Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature465(7297), 473–477 (2010).
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature463(7278), 191–196 (2010).
   PubMed Web of Science ®Google Scholar
• Ledford H. Big science: the cancer genome challenge. Nature464(7291), 972–974 (2010).
   PubMed Web of Science ®Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol.7(9), 493–507 (2010).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature458(7236), 290–292 (2009).
   PubMedGoogle Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9(7), 463–475 (2009).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med.353(16), 1734–1736 (2005).
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist13(6), 620–630 (2008).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.20, 1319–1329 (2009).
   PubMed Web of Science ®Google Scholar
• Jenkintown PA. National Comprehensive Cancer Network. Guidelines for treatment of cancer by site. National Comprehensive Cancer Network (2009).
   Google Scholar
• Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics11(8), 1039–1043 (2010).
   PubMedGoogle Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol.27(Suppl.), 18s (2009) (Abstract LBA4509).
   Google Scholar
• Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol.17, 14–17 (2010).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn.10(3), 247–250 (2010).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics11(3), 283–287 (2010).
   PubMed Web of Science ®Google Scholar
• Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature456, 728–731 (2008).
   PubMed Web of Science ®Google Scholar
• Manolio TA. Genome-wide association studies and assessment of the risk of disease. N. Engl. J. Med.363(2), 166–176 (2010).
   PubMed Web of Science ®Google Scholar
• Beaudet AL. Which way for genetic-test regulation? Leave test interpretation to specialists. Nature466(7308), 816–817 (2010).
   PubMed Web of Science ®Google Scholar
• Evans JP, Dale DC, Fomous C. Preparing for a consumer-driven genomic age. N. Engl. J. Med. DOI: 10.1056/NEJMp1006202 (2010) (Epub ahead of print).
   Google Scholar
• Annes JP, GiovanniMA, Murray MF. Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med. DOI: 10.1056/NEJMp1006029 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med.4(4), 583–586 (2010).
   PubMed Web of Science ®Google Scholar
• Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Personalized. Med.7(4), 347–350. DOI 10.2217/PME.10.30 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn.10(5), 541–545 (2010).
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA102, 10604–10609 (2005).
   PubMed Web of Science ®Google Scholar
• Time for the epigenome. Nature463(7281), 587 (2010)
   Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N. Engl. J. Med.358(11), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Katsnelson A. Genomics goes beyond DNA sequence. Nature465(7295), 145 (2010).
   PubMed Web of Science ®Google Scholar
• Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature461(7261), 218–223 (2009).
   PubMed Web of Science ®Google Scholar
• Rockman MV. Reverse engineering the genotype–phenotype map with natural genetic variation. Nature456, 738–744 (2008).
   PubMed Web of Science ®Google Scholar
• Bohman T. Mathematics. Emergence of connectivity in networks. Science323(5920), 1438–1439 (2009).
   PubMedGoogle Scholar
• Wood SN. Statistical inference for noisy nonlinear ecological dynamic systems. Nature466(7310), 1102–1104 (2010).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn.10(1), 33–48 (2010)
   PubMed Web of Science ®Google Scholar